Biotech Breakthrough? Hemab Bags $157M to Rewrite the Rulebook on Rare Blood Diseases

Hemab Therapeutics, a biotech company developing next-generation therapeutics for underserved bleeding and thrombotic disorders, has raised a $157 million Series C round. The financing was co-led by Access Biotechnology and Deep Track Capital, with participation from Avoro Ventures, Invus, Rock Springs Capital, and other top-tier investors. Hemab has now raised over $300 million in total, signaling continued confidence in its platform and pipeline.

The fresh capital will be used to fund the completion of the ongoing Phase 1/2 trial of HMB-001, the company’s lead candidate for Glanzmann Thrombasthenia, a rare inherited bleeding disorder with no approved treatments. Additionally, it will accelerate the broader development of Hemab’s Hemab 2030 pipeline, which aims to launch one investigational program per year through the end of the decade — including promising assets targeting factor VII deficiency, von Willebrand disease, and congenital antithrombin deficiency.

Hemab stands out by focusing exclusively on rare bleeding and thrombotic diseases, a largely neglected space despite serious unmet needs. Unlike many players in hemophilia alone, Hemab is targeting a broader spectrum of rare disorders with a modular antibody-based platform inspired by the success of oncology biologics.

The Danish-American biotech — headquartered in Copenhagen with R&D in Boston — is positioning itself as a global leader in hematology innovation. The Series C will support its push to deliver the first approved therapies for several ultra-rare diseases and build a fully integrated, commercial-stage biotech within the next few years.

Source: Hemab Therapeutics
                 Endpoints News

M.A.